Highlights Athira Pharma, Inc.

Equities

ATHA

US04746L1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
2.57 ^USD	+4.90%		+0.78%	+5.76%

May. 15	Athira Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 15	Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Athira Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease	Apr. 11	CI
Athira Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis	Feb. 08	CI
Athira Pharma, Inc. Provides 2024 Clinical Pipeline Outlook	Jan. 08	CI
Athira Pharma, Inc. Completes Enrollment of Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer's Disease	Jan. 03	CI
Athira Pharma, Inc. Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-B-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease	Nov. 15	CI
Athira Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Athira Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Athira Pharma, Inc. Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimerâ€™s Disease	23-07-17	CI
Athira Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Athira Pharma, Inc. Plans to Further Extend the Current OLEX for the Phase 2/3 LIFT-AD and Phase 2 ACT-AD Trials	23-05-11	CI
Athira Pharma, Inc. Presents New Clinical and Preclinical Data at the American Academy of Neurology 2023 Annual Meeting	23-04-25	CI
ATHIRA PHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-23	AQ
Athira Pharma, Inc. Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics	22-12-21	CI
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND	22-12-05	CI
ATHIRA PHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-10	AQ
Athira Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Athira Pharma Gets Recommendation to Continue Fosgonimeton Study in Alzheimer's Patients; Shares Rise	22-10-17	MT
Athira Pharma Advances Phase 2/3 Lift-Ad Clinical Study of Fosgonimeton in Mild-To Moderate Alzheimer's Patients Following Independent, Unblinded Interim Analysis	22-10-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Athira Pharma, Inc.

Equities

ATHA

US04746L1044

Highlights

Filters